M
PBLA

Murchinson’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Murchinson’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6
Closed -$238K – 165
2021
Q4 		$238K Hold
6
– – 0.02% 80
2021
Q3 		$326K Hold
6
– – 0.16% 51
2021
Q2 		$425K Buy
+6
New +$585K 0.15% 63

Other funds holding PBLA

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPS
Fieldpoint Private Securities Greenwich, Connecticut $344M AUM 7.21% 1-Year Est. Return
BAMG
Brand Asset Management Group Chesterfield, Missouri $452M AUM 25.97% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Murchinson's PBLA Position: Q1 2022 in Review

Murchinson sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2022, closing a stake of 6 shares — an estimated $238K sold.

Murchinson first reported a position in PBLA in Q2 2021 and held it in 3 quarters. The position peaked at $425K in Q2 2021. 10 funds tracked by Wall St. Rank hold PBLA as of Q1 2022.

  • Murchinson reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Murchinson sold 6 Panbela Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $238K.
  • Murchinson first reported a position in Panbela Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Murchinson's Panbela Therapeutics, Inc. Common Stock position peaked at $425K in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Murchinson's 13F filing for Q1 2022, filed 12 May 2022.